Email Updates

You are here

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

Status
Ongoing
Phase
Open Label
Principal Investigator(s)
David Magnuson, PharmD
Objective

This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.

Prevention Option(s)
PrEP
Observational
Prospective Cohort
Trial Sponsors
Gilead Sciences
September 2013
June 2018
Enrollment
150
18
Years
Population
Women
Men